• Spot Biosystems

  Participated · Equity · Jun 2026

  Spot Biosystems is developing an engineered extracellular vesicle (EV) delivery platform designed to encapsulate large nucleic acid cargo and enable repeat, non-viral dosing to skeletal muscle. The company reported a peer-reviewed study in Nature Biomedical Engineering showing EV-delivered full-length dystrophin mRNA produced sustained protein expression and improved muscle function in DMD knockout mice and sustained expression without organ toxicity in non-human primates. Spot has launched an investigator-initiated first-in-human trial at Shanghai Children's Medical Center, where the first two pediatric patients demonstrated respective 1000%+ and 2000%+ increases in dystrophin after one month and functional improvement lasting up to six months after dosing cessation. The platform is positioned to overcome limitations of AAV-based approaches by supporting larger cargo and repeat dosing. Financially, Spot emerged from stealth with $40 million in venture financing from a syndicate including LDV Partners, IDG Capital, Advantech Capital, Tiger Jade Capital, Shanda Ventures, the Stanford StartX fund, and Saltagen Ventures. The company intends to use clinical data from the IIT to inform future regulatory pathways and further clinical development for Duchenne muscular dystrophy.

• Great Bay Bio

  Led · Series B · Sep 2022

  Great Bay Bio develops an end-to-end AI-enabled bioprocessing platform to satisfy R&D and commercial demands of global customers. Led by Chairman and Co-founder Kingsley Leung, the company has commercialized two proprietary AI+CMC platforms, AlfaCell® and AlfaMedX®, which have been used by multiple biopharma companies. AlfaCell® reduces uncertainties in productivity and stability in cell line development, improving efficiency in upstream bioprocess development, while AlfaMedX® maintains a culture medium library of more than one thousand formulas and enables rapid customized medium development services. GBB's AI solutions have been applied to CMC processes for fusion proteins, monoclonal antibodies, bispecific antibodies, and have supported R&D in synthetic biology, industrial enzyme preparations, cultured meat, and other biomanufacturing fields. The company raised USD15M in a Pre-Series B round and intends to use the funds to accelerate development of AI-empowered bioprocessing platforms, construct production facilities, and establish a global commercial development team. Great Bay Bio is a Hong Kong-based high-tech enterprise applying artificial intelligence and related technologies to CMC bioprocessing. The company offers three AI-driven platforms: Klone4.0™, an AI-enabled cell line selection platform; AlfaStaX®, an AI-enabled cell line stability prediction platform; and AlfaMedX®, an AI-enabled cell culture media development platform. Klone4.0 can pinpoint and select high-yield monoclones within four hours, while AlfaStaX predicts 90-day cell line stability using two weeks of real-time cell images. AlfaMedX uses big data mining, deep learning, and transfer learning to build media formulation models that replace traditional DOE and metabolic analysis, reducing development time and cost. Each platform has been commercially validated to improve bioprocess development efficiency and reduce R&D risk, and the company has formed multiple partnerships with domestic biopharmaceutical companies, MNCs and CDMOs. Great Bay Bio intends to use the proceeds from its near $10M Series A to accelerate global commercialization of its three platforms.

No current team members are available.